Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BMRN

Biomarin Pharmaceutical Inc

Feb 13 • 04:00PM ET

59.87

-0.07 -0.12 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: IJH VTI VB VBK VXF XBI MDY IBB FBT SPMD

Index	-	P/E	22.43	EPS (ttm)	2.67	Insider Own	1.10%	Shs Outstand	192.10M	Perf Week	2.99%
Market Cap	11.50B	Forward P/E	14.37	EPS next Y	4.17	Insider Trans	0.00%	Shs Float	190.00M	Perf Month	6.76%
Enterprise Value	10.63B	PEG	0.39	EPS next Q	0.21	Inst Own	95.98%	Short Float	4.16%	Perf Quarter	8.22%
Income	520.42M	P/S	3.73	EPS this Y	2.64%	Inst Trans	-3.58%	Short Ratio	2.94	Perf Half Y	3.22%
Sales	3.09B	P/B	1.90	EPS next Y	83.74%	ROA	7.20%	Short Interest	7.91M	Perf YTD	0.74%
Book/sh	31.53	P/C	7.78	EPS next 5Y	36.60%	ROE	9.07%	52W High	73.51 -18.56%	Perf Year	-7.06%
Cash/sh	7.69	P/FCF	13.82	EPS past 3/5Y	- -	ROIC	7.82%	52W Low	50.76 17.95%	Perf 3Y	-45.08%
Dividend Est.	-	EV/EBITDA	11.34	Sales past 3/5Y	15.43% 10.98%	Gross Margin	80.64%	Volatility	3.79% 2.91%	Perf 5Y	-31.22%
Dividend TTM	-	EV/Sales	3.45	EPS Y/Y TTM	60.21%	Oper. Margin	27.73%	ATR (14)	1.79	Perf 10Y	-14.57%
Dividend Ex-Date	-	Quick Ratio	3.10	Sales Y/Y TTM	12.31%	Profit Margin	16.87%	RSI (14)	60.83	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	4.83	EPS Q/Q	-129.25%	SMA20	4.04%	Beta	0.25	Target Price	88.59
Payout	0.00%	Debt/Eq	0.10	Sales Q/Q	5.98%	SMA50	5.02%	Rel Volume	0.72	Prev Close	59.94
Employees	3040	LT Debt/Eq	0.10	Earnings	Oct 27 AMC	SMA200	5.91%	Avg Volume	2.69M	Price	59.87
IPO	Jul 23, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.88% -0.17%	Trades		Volume	1,939,845	Change	-0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$80
Jan-20-26	Upgrade	Canaccord Genuity	Hold → Buy	$98
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$60
Nov-06-25	Downgrade	Stifel	Buy → Hold	$61
Sep-08-25	Initiated	H.C. Wainwright	Neutral	$60
Sep-03-25	Initiated	Raymond James	Outperform	$85
Jul-03-25	Resumed	Morgan Stanley	Overweight	$97
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102

Show Previous Ratings

Today 02:11PM	What to Expect From These Drug/Biotech Players This Earnings Season? (Zacks)
12:24PM	What Makes BioMarin (BMRN) so Attractive (Insider Monkey)
Feb-13-26 04:31PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Feb-12-26 04:05PM	BioMarin Announces Closing of Private Offering of Senior Notes (PR Newswire)
12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
10:00AM	Loading…
10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-11-26 10:00AM	Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline (Zacks)
08:30AM	Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? (Zacks)
Feb-08-26 03:49AM	What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? (Insider Monkey)
Feb-07-26 04:09AM	Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays (Insider Monkey)
Jan-31-26 05:04AM	Should You Buy BioMarin Pharmaceutical Before Feb. 18? (Motley Fool)
Jan-29-26 04:05PM	BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
06:57AM	Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Jan-27-26 07:22AM	Double-digit Revenue Growth Till 2030 Drives BioMarin's (BMRN) Bullish Thesis (Insider Monkey)
07:45AM	Loading…
Jan-26-26 07:45AM	BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-22-26 06:02AM	BioMarin vets form Mendra to modernize rare disease drug development (BioPharma Dive)
Jan-16-26 11:01AM	FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-26 10:08AM	Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical (Zacks)
08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-14-26 12:25PM	Humana Partners With Atlas to Enhance Cancer Care for Seniors (Zacks)
08:52AM	4 Value Stocks to Buy As Wall Street Weighs Trump Policies (Zacks)
Jan-13-26 11:40AM	BMRN or TARS: Which Is the Better Value Stock Right Now? (Zacks)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
09:40AM	Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? (Zacks)
05:46AM	BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference (MarketBeat)
Jan-12-26 04:05PM	BioMarin Appoints Arpit Dave Chief Digital and Information Officer (PR Newswire)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Jan-08-26 04:05PM	BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA (PR Newswire)
08:30AM	Loading…
08:30AM	Veeva and BioMarin Form Long-Term Strategic Partnership (PR Newswire)
Jan-05-26 04:26AM	10 Magnificent Stocks That Can Make You Richer in 2026 (Motley Fool)
Jan-01-26 06:29AM	H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver (Insider Monkey)
Dec-30-25 11:54AM	Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? (Insider Monkey)
Dec-29-25 09:30PM	Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio? (Benzinga)
07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-24-25 06:30AM	Spruce Biosciences initiated with an Outperform at Oppenheimer (TipRanks)
Dec-23-25 02:35PM	BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know (StockStory)
Dec-22-25 10:18PM	Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition (Insider Monkey)
09:09PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
12:27PM	BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push (Pharmaceutical Technology)
12:15PM	A $4.8 Billion Reason to Buy BioMarin Stock Today (Barchart)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
Dec-20-25 08:13AM	BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus (Insider Monkey)
Dec-19-25 04:32PM	Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal) +17.71%
04:17PM	BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus (Investor's Business Daily)
04:16PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today (StockStory)
12:41PM	Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play (GuruFocus.com)
11:57AM	BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
11:01AM	Stocks to Watch Friday: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal)
10:55AM	BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. (Barrons.com)
09:38AM	Stocks to Watch Friday: Nike, Oracle, FedEx, Sony (The Wall Street Journal)
09:06AM	BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal (Investor's Business Daily)
08:13AM	BioMarin to Buy Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
07:45AM	BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook (PR Newswire)
Dec-15-25 01:16PM	Do Options Traders Know Something About BMRN Stock We Don't? (Zacks)
Dec-11-25 07:44AM	Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges (Insider Monkey)
Dec-10-25 10:32AM	BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink (Insider Monkey)
Dec-04-25 02:15PM	BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory (Insider Monkey)
Dec-03-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? (Zacks)
Nov-27-25 11:30AM	Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? (Zacks)
Nov-24-25 11:00PM	2 Reasons to Like BMRN and 1 to Stay Skeptical (StockStory)
Nov-23-25 10:33PM	Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks (StockStory)
Nov-20-25 11:02PM	BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool)
Nov-11-25 09:00AM	BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England (PR Newswire)
Nov-04-25 09:36AM	J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Nov-03-25 12:31AM	The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical's Q3 Earnings Call (StockStory)
Oct-31-25 10:28PM	Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Oct-30-25 09:39PM	BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025 (Insider Monkey)
Oct-29-25 06:11PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
09:00AM	FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria (PR Newswire)
Oct-28-25 04:59PM	Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday (Motley Fool)
02:26PM	BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy (Zacks)
12:24PM	Why is BioMarin Pharmaceutical (BMRN) One of the Most Profitable Biotech Stocks to Buy? (Insider Monkey)
12:10PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today (StockStory)
01:31AM	BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook (StockStory)
Oct-27-25 11:00PM	BioMarin Pharmaceutical Inc (BMRN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
06:00PM	Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics (Zacks)
05:30PM	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates (Zacks)
04:32PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates (StockStory)
04:03PM	BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update (PR Newswire)
01:55PM	BioMarin, following sluggish sales, to offload hemophilia gene therapy (BioPharma Dive)
Oct-25-25 11:03PM	BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 12:43AM	3 of Wall Street's Favorite Stocks to Target This Week (StockStory)
Oct-23-25 10:00AM	Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-25 04:05PM	BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET (PR Newswire)
Oct-17-25 09:54PM	Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Oct-08-25 12:57AM	Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? (Insider Monkey)
Oct-06-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Oct-02-25 09:46AM	Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors (Insider Monkey)
Oct-01-25 08:08PM	BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low (Insider Monkey)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-30-25 04:01AM	Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT (Insider Monkey)
Sep-19-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Sep-18-25 12:39PM	BioMarin Pharmaceutical Inc.'s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials (Insider Monkey)
Sep-17-25 02:27PM	BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Sep-16-25 12:37PM	BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory (Insider Monkey)
09:51AM	New Study Results Highlight BioMarin's VOXZOGO Efficacy in Children (Insider Monkey)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	GVP, Chief Accounting Officer	May 20 '25	Sale	59.31	1,786	105,928	14,173	May 20 05:58 PM
Burkhart Erin	Officer	May 20 '25	Proposed Sale	59.31	1,786	105,928		May 20 09:58 AM
Hubbard Cristin	EVP, Chief Commercial Officer	May 02 '25	Sale	64.92	273	17,723	32,700	May 06 05:07 PM
Hubbard Cristin	Officer	May 02 '25	Proposed Sale	64.92	273	17,723		May 02 10:05 AM
Burkhart Erin	GVP, Chief Accounting Officer	Mar 19 '25	Sale	71.52	1,295	92,618	16,955	Mar 20 07:38 PM
Burkhart Erin	Officer	Mar 19 '25	Proposed Sale	71.52	1,295	92,618		Mar 19 09:36 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 06 '25	Sale	71.28	7,034	501,355	87,655	Mar 07 04:06 PM
Guyer Charles Greg	Officer	Mar 06 '25	Proposed Sale	71.28	7,034	501,359		Mar 06 04:05 PM
Burkhart Erin	GVP, Chief Accounting Officer	Feb 24 '25	Sale	68.38	1,344	91,903	13,105	Feb 25 08:21 PM
Burkhart Erin	Officer	Feb 24 '25	Proposed Sale	68.38	1,344	91,903		Feb 24 10:26 AM

Open in Screener

NKTR

Nektar Therapeutics

Feb 13 • 04:00PM ET

71.33

+0.33 0.46 %

Healthcare • Biotechnology • USA • NASD

NKTR Nektar Therapeutics daily Stock Chart

Peers: AMGN BIIB VRTX GILD REGN INCY IONS SRPT EXEL NBIX

| Held by: VTI VXF XPH SCHA IHE PRFZ LFSC VHT ITOT SCHB

Index	-	P/E	-	EPS (ttm)	-7.94	Insider Own	1.46%	Shs Outstand	20.34M	Perf Week	93.78%
Market Cap	1.45B	Forward P/E	-	EPS next Y	-9.87	Insider Trans	-10.01%	Shs Float	20.04M	Perf Month	97.64%
Enterprise Value	1.35B	PEG	-	EPS next Q	-2.42	Inst Own	80.59%	Short Float	16.40%	Perf Quarter	23.69%
Income	-120.74M	P/S	23.18	EPS this Y	-15.44%	Inst Trans	57.67%	Short Ratio	3.21	Perf Half Y	167.25%
Sales	62.60M	P/B	16.48	EPS next Y	1.74%	ROA	-39.63%	Short Interest	3.29M	Perf YTD	68.71%
Book/sh	4.33	P/C	5.37	EPS next 5Y	-9.84%	ROE	-180.24%	52W High	72.31 -1.36%	Perf Year	433.23%
Cash/sh	13.28	P/FCF	-	EPS past 3/5Y	41.29% 25.49%	ROIC	-52.50%	52W Low	0.43 16411.57%	Perf 3Y	54.39%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.15% -3.00%	Gross Margin	85.92%	Volatility	13.34% 8.32%	Perf 5Y	-79.20%
Dividend TTM	-	EV/Sales	21.53	EPS Y/Y TTM	36.87%	Oper. Margin	-217.83%	ATR (14)	4.88	Perf 10Y	-58.79%
Dividend Ex-Date	-	Quick Ratio	4.24	Sales Y/Y TTM	-32.79%	Profit Margin	-192.87%	RSI (14)	81.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.24	EPS Q/Q	29.43%	SMA20	66.57%	Beta	-1.11	Target Price	123.43
Payout	-	Debt/Eq	1.96	Sales Q/Q	-51.13%	SMA50	58.36%	Rel Volume	2.15	Prev Close	71.00
Employees	61	LT Debt/Eq	1.70	Earnings	Nov 06 AMC	SMA200	91.05%	Avg Volume	1.02M	Price	71.33
IPO	May 03, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.35% 17.26%	Trades		Volume	2,203,367	Change	0.46%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy	$102
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform

Show Previous Ratings

Feb-13-26 04:15PM	Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-11-26 10:23PM	Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering (PR Newswire) +18.48% +7.01%
08:08AM	Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? (Zacks)
07:42AM	Nektars stock rises 51% on Phase II Rezpeg AD maintenance win (Clinical Trials Arena)
07:35AM	Why Is Nektar Therapeutics Stock Gaining Wednesday? (Benzinga)
02:07AM	Loading…
02:07AM	Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 (MarketBeat)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +51.07%
04:05PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
11:57AM	Nektar Therapeutics Stock Is Trending Tuesday: What's Going On? (Benzinga)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
07:00AM	New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing (PR Newswire)
Feb-09-26 04:15PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 (PR Newswire)
Feb-02-26 10:02PM	Nektar Therapeutics (NKTR): A Bull Case Theory (Insider Monkey)
Jan-30-26 04:10PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.96%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
08:45AM	Loading…
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-21-25 07:31AM	Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) (Insider Monkey)
Dec-16-25 07:30AM	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata (PR Newswire) -7.77%
06:24AM	Nektar sees silver lining as autoimmune drug narrowly misses in alopecia study (BioPharma Dive)
Dec-15-25 06:00PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 (PR Newswire)
Dec-08-25 12:00PM	Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy (Zacks)
Dec-05-25 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-01-25 09:55AM	Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade (Zacks) -6.29%
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly) +8.85%
Nov-23-25 07:02AM	Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? (Insider Monkey)
Nov-20-25 06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool) -8.68%
Nov-13-25 09:55AM	Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect? (Zacks) -6.45%
05:45PM	Loading…
Nov-08-25 05:45PM	New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
12:07AM	Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Nov-06-25 05:55PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:06PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:00AM	Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -7.72%
Oct-30-25 06:00PM	Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire) +5.32%
10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 06:00PM	Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
09:55AM	Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High? (Zacks)
Oct-26-25 06:06AM	Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation (Insider Monkey)
Oct-22-25 08:00AM	Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Oct-13-25 08:37AM	This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street (Motley Fool) +5.63%
Oct-05-25 08:41AM	Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September (Motley Fool)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) -7.81%
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-18-25 05:34PM	Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today (Motley Fool) +15.06% -6.16%
12:23PM	EADV 25: Nektar presents data from AD candidate that sent stocks flying (Clinical Trials Arena)
08:45AM	Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 (PR Newswire)
Sep-09-25 07:00AM	Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 (PR Newswire) +9.56%
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks) +10.33%
Sep-05-25 01:32PM	Why Nektar Therapeutics Rippled Higher This Week (Motley Fool) +11.67%
Sep-03-25 07:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in September (PR Newswire) +26.02%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-08-25 06:15PM	Why Nektar Therapeutics Stock Popped 6% on Friday (Motley Fool) +6.02%
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
Aug-07-25 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-04-25 11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-31-25 06:00PM	Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets (PR Newswire) +5.90%
Jul-29-25 09:00AM	Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata (PR Newswire)
01:31AM	Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin (Insider Monkey)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
Jul-06-25 04:01AM	Nektar Therapeutics Reports Positive Phase 2b Results for Eczema Treatment Rezpegaldesleukin (Insider Monkey)
Jul-03-25 07:00PM	Why Nektar Therapeutics Stock Dived by 3% Today (Motley Fool) -5.21%
Jul-02-25 04:15PM	Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Jul-01-25 07:17AM	Nektar Therapeutics Announces Pricing of $100 Million Public Offering (PR Newswire)
Jun-30-25 04:02PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-28-25 08:15AM	Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher? (MarketBeat)
Jun-25-25 06:45PM	Why Nektar Therapeutics Stock Was Red-Hot Today (Motley Fool) +19.10%
12:20PM	Wainwright sets over $100 target for Nektar on paradigm-shifting data (TipRanks)
11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 04:23PM	Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment (Investor's Business Daily) +156.29%
10:54AM	Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results (Investopedia)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
09:07AM	Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam (Investor's Business Daily)
07:30AM	REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Jun-23-25 04:30PM	Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 (PR Newswire) +12.10%
May-13-25 05:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference (PR Newswire)
May-09-25 02:29PM	Q1 2025 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
09:08AM	Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
03:46AM	Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... (GuruFocus.com)
May-08-25 06:25PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire)
May-07-25 05:20PM	Nektar Therapeutics Q1 2025 Earnings Preview (Seeking Alpha) -5.67%
May-01-25 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-11-25 02:29PM	Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 (GuruFocus.com) +23.76%
11:30AM	Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? (Zacks)
Mar-22-25 06:57PM	Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil (Insider Monkey)
Mar-20-25 06:00PM	Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-14-25 07:33AM	Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) (Zacks) +9.98%
Mar-13-25 12:06PM	Q4 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	Jan 20 '26	Sale	35.67	3,867	137,936	21,354	Jan 22 07:31 PM
Zalevsky Jonathan	Officer	Jan 20 '26	Proposed Sale	35.67	3,867	137,946		Jan 20 04:21 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 25 '25	Sale	54.28	1,157	62,802	18,971	Nov 25 08:30 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 25 '25	Sale	54.28	630	34,196	21,585	Nov 25 08:29 PM
ROBIN HOWARD W	President & CEO	Nov 25 '25	Sale	54.28	2,207	119,796	54,245	Nov 25 08:28 PM
ROBIN HOWARD W	Officer	Nov 25 '25	Proposed Sale	58.82	2,207	129,812		Nov 25 03:35 PM
Wilson Mark Andrew	Officer	Nov 25 '25	Proposed Sale	58.82	630	37,056		Nov 25 03:32 PM
Zalevsky Jonathan	Officer	Nov 25 '25	Proposed Sale	58.82	1,157	68,053		Nov 25 03:28 PM
ROBIN HOWARD W	President & CEO	Sep 09 '25	Sale	46.69	6,666	311,214	49,342	Sep 11 09:01 PM
ROBIN HOWARD W	Officer	Sep 09 '25	Proposed Sale	46.69	6,666	311,205		Sep 09 04:57 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 04 '25	Sale	33.52	1,721	57,693	17,462	Sep 08 08:32 PM
ROBIN HOWARD W	President & CEO	Sep 05 '25	Sale	38.53	6,666	256,851	56,008	Sep 08 08:31 PM
ROBIN HOWARD W	President & CEO	Sep 04 '25	Sale	33.70	5,166	174,108	62,674	Sep 08 08:31 PM
ROBIN HOWARD W	Officer	Sep 05 '25	Proposed Sale	38.53	6,666	256,838		Sep 05 04:37 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 02 '25	Sale	30.10	485	14,598	19,183	Sep 04 09:02 PM
ROBIN HOWARD W	President & CEO	Sep 02 '25	Sale	30.16	1,500	45,240	67,840	Sep 04 09:01 PM
ROBIN HOWARD W	Officer	Sep 04 '25	Proposed Sale	33.70	5,166	174,119		Sep 04 05:06 PM
Zalevsky Jonathan	Officer	Sep 04 '25	Proposed Sale	33.52	1,721	57,688		Sep 04 04:19 PM
Zalevsky Jonathan	Officer	Sep 02 '25	Proposed Sale	30.10	485	14,600		Sep 02 04:45 PM
ROBIN HOWARD W	Officer	Sep 02 '25	Proposed Sale	30.16	1,500	45,244		Sep 02 04:42 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '25	Sale	26.59	725	19,278	19,668	Aug 21 09:05 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '25	Sale	26.59	676	17,975	20,312	Aug 21 09:04 PM
ROBIN HOWARD W	President & CEO	Aug 19 '25	Sale	26.59	1,573	41,826	69,340	Aug 21 09:03 PM
ROBIN HOWARD W	Officer	Aug 19 '25	Proposed Sale	26.59	1,573	41,826		Aug 19 03:24 PM
Wilson Mark Andrew	Officer	Aug 19 '25	Proposed Sale	26.59	676	17,975		Aug 19 03:24 PM
Zalevsky Jonathan	Officer	Aug 19 '25	Proposed Sale	26.59	725	19,278		Aug 19 03:20 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '25	Sale	0.67	10,712	7,177	305,892	May 21 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	May 19 '25	Sale	0.67	9,996	6,697	314,296	May 21 08:07 PM
ROBIN HOWARD W	President & CEO	May 19 '25	Sale	0.67	23,208	15,549	1,063,693	May 21 08:07 PM
Zalevsky Jonathan	Officer	May 19 '25	Proposed Sale	0.67	10,712	7,191		May 19 03:49 PM
Wilson Mark Andrew	Officer	May 19 '25	Proposed Sale	0.67	9,996	6,710		May 19 03:44 PM
ROBIN HOWARD W	Officer	May 19 '25	Proposed Sale	0.67	23,208	15,580		May 19 03:40 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 19 '25	Sale	1.01	10,300	10,403	316,604	Feb 21 06:07 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 19 '25	Sale	1.01	11,040	11,150	324,292	Feb 21 06:06 PM
ROBIN HOWARD W	President & CEO	Feb 19 '25	Sale	1.01	23,774	24,012	1,086,901	Feb 21 06:04 PM
Wilson Mark Andrew	Officer	Feb 19 '25	Proposed Sale	1.01	11,040	11,137		Feb 19 03:27 PM
ROBIN HOWARD W	Officer	Feb 19 '25	Proposed Sale	1.01	23,774	23,983		Feb 19 03:21 PM
Zalevsky Jonathan	Officer	Feb 19 '25	Proposed Sale	1.01	10,300	10,391		Feb 19 03:18 PM

BMRN

Biomarin Pharmaceutical Inc

NKTR

Nektar Therapeutics

Upgrade your FINVIZ experience